论著
Luo Qiang;Tu Mingli;Lei Huaiding;Liu Xianjun;Zhu Shaoming
2005, 7(3): 168-170.
Objective:To observe the effects and safety of COFETOL cough syrup and budesonide inhalation in treatment of patients with cough variant asthma(CVA). Methods: 72 cases of CVA were dividid into 3 groups: group"COFETOL+budeosonide"(n=30, mean age 35.33±18.56 yrs) receiving the two drugs, group"budesonide"(n=21, mean age 34.88±22.12yrs)receiving budesonide only, and group"prednisone"(n=21, mean age 32.67±19.55 yrs) served as control. The relief time of cough was recorded and the scores of both symptom and bronchial provocative test were added for evaluation of treatment efficiency. The adverse reactions were compared among the three groups. Results: Under the above treatment for 14 days, the effective rates were 90.00%, 90.04% and 90.48% respectively, with no differences in statistics (P> 0.05) between them. The rates of remarkable effects of group "COFETOL+budesonide" were higher than group "budesonide"(60% vs 14.29%, P<0.01),and similar to group "prednisone"(61.90%, P> 0.05). The relief time of cough on average for group "COFETOL+budesonide"(5.9±1.9 days)was obviously shorter than group "budesonide"(9.9±3.2 days, P < 0.01), and no different from group "prednisone"(6.8±2.2days, P > 0.05). Mouth mycosis infection occurred in one case of group"COFETOL+budesonide"(3.33%), hoarse voice did in one case of group "budesonide"(4.76%)and 8 cases with adverse reactions in group "prednisone"(38.09%, P < 0.01). Conclusion: The combination of COFETOL cough syrup and budesonide inhalation is a rapid, secure and new alternative method for treatment of CVA
